ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2022

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.

Douglas L Arnold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.